Key result
Adjuvant molecular hydrogen therapy improves cardiac function and fatigue in lupus-associated heart failure.
Why the study?
Does molecular hydrogen therapy improve cardiac function and reduce fatigue in a patient with severe lupus serositis and heart failure?
Case Report (n=1)
Does molecular hydrogen therapy improve cardiac function and reduce fatigue in a patient with severe lupus serositis and heart failure?
Answers are grounded in this paper and cite their sources.
Molecular hydrogen therapy may serve as a beneficial adjuvant treatment for improving cardiac function and reducing fatigue in patients with SLE-associated heart failure.
Background/Aim: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multi-organ inflammation and damage across multiple organs, typically managed with steroids and immunomodulators. However, prolonged use of these treatments is often associated with significant side effects, underscoring the need for adjunctive therapies that improve disease outcomes while minimizing adverse effects. Molecular hydrogen (H₂) has demonstrated potential as an antioxidant and anti-inflammatory agent. This report discusses a case of SLE with cardiac complications, evaluating the therapeutic impact of molecular hydrogen therapy on fatigue, immune modulation, and cardiac function. Case Report: A 51-year-old female with SLE and acute decompensated heart failure initially received steroids and immunomodulators for disease management. Subsequently, molecular hydrogen therapy was introduced as an adjuvant treatment. Over several months, her cardiac function showed notable improvement, evidenced by reductions in anti-dsDNA and anti-Ro52 antibody levels, and Pro-BNP levels, as well as favorable shifts in T and B cell subsets. Additionally, the patient experienced a significant reduction in fatigue. She successfully tapered off steroids while maintaining disease stability with ongoing molecular hydrogen therapy. Conclusion: This case highlights the potential of molecular hydrogen therapy as an adjuvant treatment in SLE, with observed benefits in immune modulation and fatigue reduction. Further studies are warranted to elucidate its therapeutic role and applicability in autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
LIN et al. (2025) conducted a case report in Systemic lupus erythematosus (SLE) with acute decompensated heart failure (n=1). Molecular hydrogen therapy was evaluated on Cardiac function, antibody levels, Pro-BNP levels, and fatigue. Adjuvant molecular hydrogen therapy in a 51-year-old female with SLE and heart failure improved cardiac function, reduced fatigue, and enabled steroid tapering.
Synapse has enriched 10 related papers. Consider them for comparative context: